Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 2.31
NAS:AERI's Cash-to-Debt is ranked higher than
52% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. NAS:AERI: 2.31 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AERI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 1.68 Max: No Debt
Current: 2.31
0.32
No Debt
Equity-to-Asset 0.55
NAS:AERI's Equity-to-Asset is ranked lower than
63% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NAS:AERI: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AERI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.55  Med: 0.55 Max: 0.55
Current: 0.55
Debt-to-Equity 0.64
NAS:AERI's Debt-to-Equity is ranked lower than
71% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. NAS:AERI: 0.64 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:AERI' s Debt-to-Equity Range Over the Past 10 Years
Min: -795.55  Med: 0.94 Max: 6.56
Current: 0.64
-795.55
6.56
Debt-to-EBITDA -0.67
NAS:AERI's Debt-to-EBITDA is ranked lower than
99.99% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. NAS:AERI: -0.67 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:AERI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.59  Med: -1.3 Max: -0.16
Current: -0.67
-2.59
-0.16
Piotroski F-Score: 5
Altman Z-Score: 6.97
WACC vs ROIC
6.78%
-1312.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -7799.22
NAS:AERI's Operating Margin % is ranked lower than
97% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. NAS:AERI: -7799.22 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AERI' s Operating Margin % Range Over the Past 10 Years
Min: -7799.22  Med: 0 Max: 0
Current: -7799.22
-7799.22
0
Net Margin % -7701.53
NAS:AERI's Net Margin % is ranked lower than
98% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. NAS:AERI: -7701.53 )
Ranked among companies with meaningful Net Margin % only.
NAS:AERI' s Net Margin % Range Over the Past 10 Years
Min: -7701.53  Med: 0 Max: 0
Current: -7701.53
-7701.53
0
ROE % -102.41
NAS:AERI's ROE % is ranked lower than
91% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. NAS:AERI: -102.41 )
Ranked among companies with meaningful ROE % only.
NAS:AERI' s ROE % Range Over the Past 10 Years
Min: -317.68  Med: -120.45 Max: -98.81
Current: -102.41
-317.68
-98.81
ROA % -55.96
NAS:AERI's ROA % is ranked lower than
88% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. NAS:AERI: -55.96 )
Ranked among companies with meaningful ROA % only.
NAS:AERI' s ROA % Range Over the Past 10 Years
Min: -930.6  Med: -51.26 Max: -41.8
Current: -55.96
-930.6
-41.8
ROC (Joel Greenblatt) % -553.68
NAS:AERI's ROC (Joel Greenblatt) % is ranked lower than
89% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. NAS:AERI: -553.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AERI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -25540.32  Med: -12090.4 Max: -553.68
Current: -553.68
-25540.32
-553.68
3-Year EBITDA Growth Rate -27.20
NAS:AERI's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NAS:AERI: -27.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:AERI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34.8  Med: -5.65 Max: 43.6
Current: -27.2
-34.8
43.6
3-Year EPS without NRI Growth Rate -27.10
NAS:AERI's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. NAS:AERI: -27.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AERI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -4.1 Max: 44
Current: -27.1
0
44
GuruFocus has detected 1 Warning Sign with Aerie Pharmaceuticals Inc NAS:AERI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AERI's 30-Y Financials

Financials (Next Earnings Date: 2018-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

AERI Guru Trades in Q3 2017

Steven Cohen 51,900 sh (New)
Paul Tudor Jones 11,010 sh (+15.16%)
Ron Baron 6,156 sh (+11.70%)
David Tepper 169,799 sh (-10.54%)
» More
Q4 2017

AERI Guru Trades in Q4 2017

Ron Baron 7,351 sh (+19.41%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
David Tepper Sold Out
» More
Q1 2018

AERI Guru Trades in Q1 2018

Ron Baron 14,769 sh (+100.91%)
» More
Q2 2018

AERI Guru Trades in Q2 2018

Steven Cohen 182,300 sh (New)
Ron Baron 25,068 sh (+69.73%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AERI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2018-06-30 Add 69.73%$47.85 - $70.45 $ 57.803%25,068
Ron Baron 2018-03-31 Add 100.91%$51.15 - $61 $ 57.803%14,769
Ron Baron 2017-12-31 Add 19.41%$50.85 - $65.1 $ 57.80-5%7,351
David Tepper 2017-12-31 Sold Out 0.12%$50.85 - $65.1 $ 57.80-5%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Aerie Pharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2836
Compare:XSWX:COPN, HKSE:01666, SGX:H02, SHSE:600252, SHSE:600568, SHSE:600664, SZSE:002004, XKRX:000100, SZSE:000591, BOM:530019, SZSE:002262, SHSE:600420, SZSE:002437, BOM:524816, XKRX:069620, SZSE:300267, BOM:532331, SZSE:300026, BOM:500674, BOM:500488 » details
Traded in other countries:0P0.Germany,
Headquarter Location:USA
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is engaged in the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its main products are Rhopressa and Roclatan. The company mainly operates in North America.

Ratios

vs
industry
vs
history
PB Ratio 11.81
AERI's PB Ratio is ranked lower than
94% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. AERI: 11.81 )
Ranked among companies with meaningful PB Ratio only.
AERI' s PB Ratio Range Over the Past 10 Years
Min: 11.14  Med: 12.93 Max: 15
Current: 11.81
11.14
15
PS Ratio 932.27
AERI's PS Ratio is ranked lower than
99% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. AERI: 932.27 )
Ranked among companies with meaningful PS Ratio only.
AERI' s PS Ratio Range Over the Past 10 Years
Min: 879.03  Med: 1020.16 Max: 1183.87
Current: 932.27
879.03
1183.87
EV-to-EBIT -13.17
AERI's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. AERI: -13.17 )
Ranked among companies with meaningful EV-to-EBIT only.
AERI' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.6  Med: -12.4 Max: -10.6
Current: -13.17
-14.6
-10.6
EV-to-EBITDA -13.31
AERI's EV-to-EBITDA is ranked lower than
99.99% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. AERI: -13.31 )
Ranked among companies with meaningful EV-to-EBITDA only.
AERI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.7  Med: -12.6 Max: -10.7
Current: -13.31
-14.7
-10.7
EV-to-Revenue 1011.86
AERI's EV-to-Revenue is ranked lower than
98% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. AERI: 1011.86 )
Ranked among companies with meaningful EV-to-Revenue only.
AERI' s EV-to-Revenue Range Over the Past 10 Years
Min: 814.9  Med: 956.5 Max: 1120.7
Current: 1011.86
814.9
1120.7
Current Ratio 10.27
AERI's Current Ratio is ranked higher than
91% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. AERI: 10.27 )
Ranked among companies with meaningful Current Ratio only.
AERI' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 11.81 Max: 24.53
Current: 10.27
0.39
24.53
Quick Ratio 10.07
AERI's Quick Ratio is ranked higher than
92% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. AERI: 10.07 )
Ranked among companies with meaningful Quick Ratio only.
AERI' s Quick Ratio Range Over the Past 10 Years
Min: 0.39  Med: 11.81 Max: 24.53
Current: 10.07
0.39
24.53
Days Inventory 8.00
AERI's Days Inventory is ranked higher than
97% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. AERI: 8.00 )
Ranked among companies with meaningful Days Inventory only.
AERI' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8
Current: 8
0
8
Days Sales Outstanding 169.47
AERI's Days Sales Outstanding is ranked lower than
89% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. AERI: 169.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
AERI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0  Med: 0 Max: 169.47
Current: 169.47
0
169.47
Days Payable 54.00
AERI's Days Payable is ranked lower than
67% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. AERI: 54.00 )
Ranked among companies with meaningful Days Payable only.
AERI' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 54
Current: 54
0
54

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.40
AERI's 3-Year Average Share Buyback Ratio is ranked lower than
73% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.30 vs. AERI: -15.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AERI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -202.6  Med: -15.15 Max: -12.8
Current: -15.4
-202.6
-12.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 18.01
AERI's Price-to-Net-Cash is ranked lower than
65% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.41 vs. AERI: 18.01 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AERI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.32  Med: 13.65 Max: 85.85
Current: 18.01
6.32
85.85
Price-to-Net-Current-Asset-Value 16.75
AERI's Price-to-Net-Current-Asset-Value is ranked lower than
84% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.66 vs. AERI: 16.75 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AERI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.26  Med: 13.25 Max: 74.85
Current: 16.75
6.26
74.85
Price-to-Tangible-Book 11.82
AERI's Price-to-Tangible-Book is ranked lower than
89% of the 749 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. AERI: 11.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AERI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.24  Med: 12.02 Max: 34.3
Current: 11.82
6.24
34.3
Price-to-Median-PS-Value 0.91
AERI's Price-to-Median-PS-Value is ranked lower than
51% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. AERI: 0.91 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AERI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.91  Med: 1.06 Max: 1.06
Current: 0.91
0.91
1.06
Earnings Yield (Greenblatt) % -7.60
AERI's Earnings Yield (Greenblatt) % is ranked lower than
80% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. AERI: -7.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AERI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.4  Med: -8 Max: -6.9
Current: -7.6
-9.4
-6.9

More Statistics

Revenue (TTM) (Mil) $2.42
EPS (TTM) $ -4.97
Beta0.64
Volatility46.45%
52-Week Range $47.06 - 74.75
Shares Outstanding (Mil)45.22

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 23 111 276 481
EBIT (Mil $) -140 -45 109 222
EBITDA (Mil $)
EPS ($) -4.27 -1.87 1.61 4.64
EPS without NRI ($) -4.27 -1.87 1.61 4.64
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}